J
Joachim Kalmus
Researcher at Bayer
Publications - 19
Citations - 1005
Joachim Kalmus is an academic researcher from Bayer. The author has contributed to research in topics: Regorafenib & Placebo. The author has an hindex of 8, co-authored 19 publications receiving 852 citations. Previous affiliations of Joachim Kalmus include Bayer HealthCare Pharmaceuticals.
Papers
More filters
Journal ArticleDOI
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li,Shukui Qin,Rui-Hua Xu,Thomas Yau,Brigette B.Y. Ma,Hongming Pan,Jianming Xu,Yuxian Bai,Yihebali Chi,Liwei Wang,Kun-Huei Yeh,F. Bi,Ying Cheng,Anh Tuan Le,Jen Kou Lin,Tianshu Liu,Dong Ma,Christian Kappeler,Joachim Kalmus,Tae Won Kim +19 more
TL;DR: This phase 3 trial is the second to show an overall survival benefit with regorafenib compared with placebo in patients with treatment-refractory metastatic metastatic colorectal cancer, substantiating the role of regorAFenib.
Journal ArticleDOI
Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.
Franck Morschhauser,Timothy M Illidge,Damien Huglo,Giovanni Martinelli,Giovanni Paganelli,Pier Luigi Zinzani,Simon Rule,Anna Marina Liberati,Noel Milpied,Georg Hess,Harald Stein,Joachim Kalmus,Robert Marcus +12 more
TL;DR: Y-ibritumomab is active in patients with relapsed and refractory diffuse large B-cell lymphoma (DLBCL) and its further evaluation in phase 3 studies is ongoing.
Journal ArticleDOI
Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study
Eric Van Cutsem,Erika Martinelli,Stefano Cascinu,Alberto Sobrero,Maria Banzi,Jean Francois Seitz,Carlo Barone,Marc Ychou,Marc Peeters,Baruch Brenner,Baruch Brenner,Ralf Hofheinz,Evaristo Maiello,Thierry André,Andrea Spallanzani,Rocio Garcia-Carbonero,Yull Edwin Arriaga,Udit Verma,Axel Grothey,Christian Kappeler,Ashok Miriyala,Joachim Kalmus,Alfredo Falcone,Alberto Zaniboni +23 more
TL;DR: The CONSIGN trial confirmed the safety profile of regorafenib from the phase III trials and reinforced the importance of using treatment modifications to manage adverse events.
Journal ArticleDOI
Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma
Anton Hagenbeek,Houchingue Eghbali,Silvio Monfardini,Umberto Vitolo,Peter Hoskin,Christiane de Wolf-Peeters,Ken MacLennan,Elvira Staab-Renner,Joachim Kalmus,Astrid Schott,I. Teodorovic,Anastassia Negrouk,Martine Van Glabbeke,Robert Marcus +13 more
TL;DR: Overall response rates were significantly improved in the fludarabine arm versus the CVP arm, both for the intent-to-treat (ITT) population and assessable patients (P < .001).
Journal ArticleDOI
Yttrium-90 Ibritumomab Tiuxetan (Zevalin) for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Appropriate for Autologous Stem Cell Transplantation: Results of an Open-Label Phase II Trial.
Franck Morschhauser,Damien Huglo,Giovanni Martinelli,Giovanni Paganelli,P. L. Zinzani,D. Hadjiyiannakis,Anna Marina Liberati,Timothy M Illidge,Noel Milpied,Harald Stein,Joachim Kalmus,Pierre Morel,U. Reimann,Robert Marcus +13 more
TL;DR: The results of this study support a further evaluation of 90Y ibritumomab tiuxetan in combination with chemotherapy or immuno-chemotherapy earlier in the time course of DLBCL.